No Data
No Data
Satellos Bioscience Inc. Brief: Adds Trial Will Evaluate the Safety and Pharmacokinetic Properties of SAT-3247 in Healthy Human Volunteers
07:16 AM EDT, 06/27/2024 (MT Newswires) -- Satellos Bioscience Inc. Brief: Adds Trial will evaluate the safety and pharmacokinetic properties of SAT-3247 in healthy human volunteers
Satellos Bioscience Inc. Brief: Co Says Intends to Submit a Regulatory Package in July to Initiate a First-in-human Phase 1 Clinical Trial, in Q3 2024
07:16 AM EDT, 06/27/2024 (MT Newswires) -- Satellos Bioscience Inc. Brief: Co Says intends to submit a regulatory package in July to initiate a first-in-human Phase 1 clinical trial, in Q3 2024
Satellos Bioscience Inc. Brief: Says CEO Frank Gleeson Participating at Parent Project Muscular Dystrophy (PPMD) 30th Annual Conference
07:15 AM EDT, 06/27/2024 (MT Newswires) -- Satellos Bioscience Inc. Brief: Says CEO Frank Gleeson Participating at Parent Project Muscular Dystrophy (PPMD) 30th Annual Conference
Satellos Bioscience Inc. Opens the Market
TORONTO, May 15, 2024 /PRNewswire/ - Frank Gleeson Co-Founder and Chief Executive Officer, Satellos Bioscience Inc. (TSX: MSCL) ("Satellos" or the "Company"), and his team joined Dani Lipkin, Managin
Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders
Satellos Bioscience Q1 Loss Widens Due To Higher Expenses; But Says "On Track" to Initiate Phase 1 First-in-human Clinical Trials Mid-2024
Satellos Bioscience Inc. (MSCL.TO), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, earlier on Tuesday reported